

# PRODUCT INFORMATION



## ONO-4059 (hydrochloride)

Item No. 32818

**CAS Registry No.:** 1439901-97-9  
**Formal Name:** 6-amino-7,9-dihydro-9-[(3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-8H-purin-8-one, monohydrochloride

**Synonyms:** GS-4059, ONO-WG-307

**MF:** C<sub>25</sub>H<sub>22</sub>N<sub>6</sub>O<sub>3</sub> • HCl

**FW:** 490.9


**Purity:** ≥98%

**UV/Vis.:** λ<sub>max</sub>: 215 nm

**Supplied as:** A crystalline solid

**Storage:** -20°C

**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

ONO-4059 (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the ONO-4059 (hydrochloride) in the solvent of choice, which should be purged with an inert gas. ONO-4059 (hydrochloride) is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of ONO-4059 (hydrochloride) in these solvents is approximately 1 mg/ml.

ONO-4059 (hydrochloride) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, ONO-4059 (hydrochloride) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. ONO-4059 (hydrochloride) has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

ONO-4059 is an inhibitor of Bruton's tyrosine kinase (BTK; IC<sub>50</sub> = 2.2 nM).<sup>1</sup> It is selective for BTK over LCK, LYN, and Fyn at 1 μM.<sup>2</sup> ONO-4059 inhibits B cell proliferation and activation *in vitro* and reduces tumor growth in a TMD8 mouse xenograft model.<sup>1,3</sup>

### References

1. Burger, A. Bruton's tyrosine kinase (BTK) inhibitors in clinical trials. *Curr. Hematol. Malig. Rep.* **9(1)**, 44-49 (2014).
2. Yasuhiro, T., Yoshizawa, T., Daub, H., *et al.* Abstract 2021: ONO-WG-307, a novel, potent and selective inhibitor of Bruton's tyrosine kinase (Btk), results in sustained inhibition of the ERK, AKT and PKD signaling pathways. *Cancer Res.* **72(8 Supplement)**, 2021 (2012).
3. Kozaki, R., Yoshizawa, T., Tohda, S., *et al.* Abstract 3731: Development of a Bruton's tyrosine kinase (Btk) inhibitor, ONO-WG-307: Efficacy in ABC-DLBCL xenograft model – potential treatment for B-cell malignancies. *Blood* **118(21)**, 3731 (2011).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/10/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM